- published: 21 Jul 2014
- views: 90809
Create your page here
-
remove the playlistAids Virus Research
-
remove the playlistLatest Videos
-
remove the playlistLongest Videos
- remove the playlistAids Virus Research
- remove the playlistLatest Videos
- remove the playlistLongest Videos
back to playlist
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple.
In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 29 May 2013
- views: 44360
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Twitter: https://twitter.com/jhug00
Read More:
New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine
http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0
"A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday."
HIV vaccine that transforms cell DNA brings fresh hope
http://www.bbc.com/news/health-31511244
"A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report."
Designer protein 'blocks all known strains of HIV'
http://www.medicalnewstoday.com/articles/289611.php
"A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative."
____________________
DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.
Watch More DNews on TestTube http://testtube.com/dnews
Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel
DNews on Twitter http://twitter.com/dnews
Trace Dominguez on Twitter https://twitter.com/tracedominguez
Julia Wilde on Twitter https://twitter.com/julia_sci
DNews on Facebook https://facebook.com/DiscoveryNews
DNews on Google+ http://gplus.to/dnews
Discovery News http://discoverynews.com
Download the TestTube App: http://testu.be/1ndmmMq
- published: 20 Feb 2015
- views: 229018
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate
degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination
with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in
the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused
on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic
potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his
supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a
group that is steadily expanding, with the aid of new enthusiast medical and doctoral students.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
- published: 09 May 2017
- views: 1153
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus.
Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu
Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU
Social Media Links:
Facebook : https://www.facebook.com/TimesofIndia
Twitter : https://twitter.com/timesofindia
Google + : https://plus.google.com/u/0/+timesindia/posts
'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM
Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd.
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection.
- published: 09 Jun 2015
- views: 3700
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona.
After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months.
Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART).
Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN.
But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives.
Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”.
“Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent.
Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles.
“The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said.
Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus.
The trial participants continued to take ART for three years, while the researchers monitored their immune responses.
Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant.
The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months.
In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful.
More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust.
- published: 04 Mar 2017
- views: 8430
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 24 Apr 2014
- views: 2128
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513
This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown.
ANH13111
- published: 25 Nov 2013
- views: 1403229
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpaint.com/
And other 3D animation videos visit
http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library
Regards,
Dr.Rufus
The Lyrics of this video is here
Targeting HIV replication
The replication of HIV 1 is a multi-stage process.
Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs.
Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte.
Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4.
These receptors interact with protein-complexes, which are embedded in the viral envelope.
These complexes are composed of two glycoproteins:
an extracellular gp 120 and
a transmembrane gp 41
When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment.
It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120.
This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane.
Gp 41 then folds back on itself.
This draws the virus towards the cell and facilitates the fusion of their membranes.
The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes:
Integrase, Protease and Reverse Transcriptase.
Reverse Transcriptase begins the reverse transcription of viral RNA.
It has two catalytic domains:
The Ribonuclease-H active site
And the polymerase active site
Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA.
The polymerase then completes the remaining DNA-strand to form a DNA -- double helix.
Now Integrase goes into action.
It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends.
Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome.
The host cell genome now contains the genetic information of HIV.
Activation of the cell induces transcription of proviral DNA into messenger RNA.
The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised.
Some of them have to be processed by the viral protease.
Protease cleaves longer proteins into smaller core proteins.
This step is crucial to create an infectious virus.
Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid.
This immature particle leaves the cell acquiring a new envelope of host and viral proteins.
The virus matures and becomes ready to infect other cells.
HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression.
Drugs which interfere with the key steps of viral replication can stop this fatal process.
Entry into the host cell can be blocked by fusion inhibitors for example.
Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens.
The action of Integrase can be blocked.
Protease inhibitors are also part of standard antiretroviral therapy.
Each blocked step in viral replication is a step towards better control of HIV disease.
Script, Storyboard, Art Direction by: Frank Schauder, MD
Animation: MACKEVISION
Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS.,
- published: 03 Mar 2007
- views: 1707274
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity."
http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/
http://www.wochit.com
This video was produced by YT Wochit News using http://wochit.com
- published: 11 Jul 2017
- views: 143
HIV
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including pyroptosis of abortively infected T cells,apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/HIV
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
location on Google Map
University of Illinois at Urbana–Champaign
The University of Illinois at Urbana–Champaign (U of I, University of Illinois, UIUC, or simply Illinois) is a public research-intensive university in the U.S. state of Illinois. A land-grant university, it is the flagship campus of the University of Illinois system. The University of Illinois at Urbana–Champaign (founded, 1867) is the second oldest public university in the state (after Illinois State University), and is a founding member of the Big Ten Conference. It is a member of the Association of American Universities and is designated as a RU/VH Research University (very high research activities). The campus library system possesses the second-largest university library in the United States after Harvard University.
The university comprises 17 colleges that offer more than 150 programs of study. Additionally, the university operates an extension that serves 2.7 million registrants per year around the state of Illinois and beyond. The campus holds 647 buildings on 4,552 acres (1,842 ha) in the twin cities of Champaign and Urbana (together known as Champaign–Urbana); its annual operating budget in 2011 was over $1.7 billion.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/University_of_Illinois_at_Urbana–Champaign
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
2:52Researchers successfully eliminate HIV virus from cultured human cells
Researchers successfully eliminate HIV virus from cultured human cellsResearchers successfully eliminate HIV virus from cultured human cells
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple. In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA. -
7:30Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 CapsidTargeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois. Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman. To read the press release about this research, please visit: http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html -
3:48Will We Ever Cure HIV?
Will We Ever Cure HIV?Will We Ever Cure HIV?
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure? Follow Julian on Twitter: https://twitter.com/jhug00 Read More: New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0 "A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday." HIV vaccine that transforms cell DNA brings fresh hope http://www.bbc.com/news/health-31511244 "A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report." Designer protein 'blocks all known strains of HIV' http://www.medicalnewstoday.com/articles/289611.php "A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative." ____________________ DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily. Watch More DNews on TestTube http://testtube.com/dnews Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel DNews on Twitter http://twitter.com/dnews Trace Dominguez on Twitter https://twitter.com/tracedominguez Julia Wilde on Twitter https://twitter.com/julia_sci DNews on Facebook https://facebook.com/DiscoveryNews DNews on Google+ http://gplus.to/dnews Discovery News http://discoverynews.com Download the TestTube App: http://testu.be/1ndmmMq -
14:11The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversityThe Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS. Mohamed Mahdi, 37, Sudan After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a group that is steadily expanding, with the aid of new enthusiast medical and doctoral students. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx -
1:57HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A WayHIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU Social Media Links: Facebook : https://www.facebook.com/TimesofIndia Twitter : https://twitter.com/timesofindia Google + : https://plus.google.com/u/0/+timesindia/posts 'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd. Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection. -
1:135 People with HIV are now Virus Free - New Vaccine Treatment
5 People with HIV are now Virus Free - New Vaccine Treatment5 People with HIV are now Virus Free - New Vaccine Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona. After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months. Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART). Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN. But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives. Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”. “Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent. Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles. “The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said. Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus. The trial participants continued to take ART for three years, while the researchers monitored their immune responses. Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant. The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months. In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful. More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust. -
7:29Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois. Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman. To read the press release about this research, please visit: http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html -
6:52Medical Animation: HIV and AIDS
Medical Animation: HIV and AIDSMedical Animation: HIV and AIDS
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513 This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown. ANH13111 -
5:14HIV Replication 3D Medical Animation
HIV Replication 3D Medical AnimationHIV Replication 3D Medical Animation
It is a very excellent animation which explains the hiv replication very clearly. For free download of this video please visit my webpage http://3dmed.wetpaint.com/ And other 3D animation videos visit http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library Regards, Dr.Rufus The Lyrics of this video is here Targeting HIV replication The replication of HIV 1 is a multi-stage process. Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs. Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte. Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4. These receptors interact with protein-complexes, which are embedded in the viral envelope. These complexes are composed of two glycoproteins: an extracellular gp 120 and a transmembrane gp 41 When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment. It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120. This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane. Gp 41 then folds back on itself. This draws the virus towards the cell and facilitates the fusion of their membranes. The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes: Integrase, Protease and Reverse Transcriptase. Reverse Transcriptase begins the reverse transcription of viral RNA. It has two catalytic domains: The Ribonuclease-H active site And the polymerase active site Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA. The polymerase then completes the remaining DNA-strand to form a DNA -- double helix. Now Integrase goes into action. It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends. Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome. The host cell genome now contains the genetic information of HIV. Activation of the cell induces transcription of proviral DNA into messenger RNA. The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised. Some of them have to be processed by the viral protease. Protease cleaves longer proteins into smaller core proteins. This step is crucial to create an infectious virus. Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid. This immature particle leaves the cell acquiring a new envelope of host and viral proteins. The virus matures and becomes ready to infect other cells. HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression. Drugs which interfere with the key steps of viral replication can stop this fatal process. Entry into the host cell can be blocked by fusion inhibitors for example. Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens. The action of Integrase can be blocked. Protease inhibitors are also part of standard antiretroviral therapy. Each blocked step in viral replication is a step towards better control of HIV disease. Script, Storyboard, Art Direction by: Frank Schauder, MD Animation: MACKEVISION Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS., -
0:45Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
Researchers Say Immune System May Prevent Body From Neutralizing HIV VirusResearchers Say Immune System May Prevent Body From Neutralizing HIV Virus
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity." http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
-
Researchers successfully eliminate HIV virus from cultured human cells
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple. In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
published: 21 Jul 2014 -
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, ele...
published: 29 May 2013 -
Will We Ever Cure HIV?
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure? Follow Julian on Twitter: https://twitter.com/jhug00 Read More: New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0 "A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday." HIV vaccine that transforms cell DNA brings fresh hope http://www.bbc.com/news/health-31511244 "A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report." Designer protein 'blocks a...
published: 20 Feb 2015 -
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS. Mohamed Mahdi, 37, Sudan After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his supervisor Prof. József Tő...
published: 09 May 2017 -
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU Social Media Links: Facebook : https://www.facebook.com/TimesofIndia Twitter : https://twitter.com/timesofindia Google + : https://plus.google.com/u/0/+timesindia/posts 'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd. Researchers have identified a protein that could help impr...
published: 09 Jun 2015 -
5 People with HIV are now Virus Free - New Vaccine Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona. After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months. Lead scientist Beatriz Mothe said he...
published: 04 Mar 2017 -
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, ele...
published: 24 Apr 2014 -
Medical Animation: HIV and AIDS
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513 This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown. ANH13111
published: 25 Nov 2013 -
HIV Replication 3D Medical Animation
It is a very excellent animation which explains the hiv replication very clearly. For free download of this video please visit my webpage http://3dmed.wetpaint.com/ And other 3D animation videos visit http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library Regards, Dr.Rufus The Lyrics of this video is here Targeting HIV replication The replication of HIV 1 is a multi-stage process. Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs. Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte. Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4. These receptors interact with protein-co...
published: 03 Mar 2007 -
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity." http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/ http://www.woc...
published: 11 Jul 2017
Researchers successfully eliminate HIV virus from cultured human cells
- Order: Reorder
- Duration: 2:52
- Updated: 21 Jul 2014
- views: 90809
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV...
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple.
In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
https://wn.com/Researchers_Successfully_Eliminate_Hiv_Virus_From_Cultured_Human_Cells
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple.
In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
- published: 21 Jul 2014
- views: 90809
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
- Order: Reorder
- Duration: 7:30
- Updated: 29 May 2013
- views: 44360
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the viru...
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
https://wn.com/Targeting_The_Hiv_Virus_Researchers_Use_Supercomputer_To_Solve_The_Structure_Of_The_Hiv_1_Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 29 May 2013
- views: 44360
Will We Ever Cure HIV?
- Order: Reorder
- Duration: 3:48
- Updated: 20 Feb 2015
- views: 229018
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Tw...
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Twitter: https://twitter.com/jhug00
Read More:
New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine
http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0
"A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday."
HIV vaccine that transforms cell DNA brings fresh hope
http://www.bbc.com/news/health-31511244
"A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report."
Designer protein 'blocks all known strains of HIV'
http://www.medicalnewstoday.com/articles/289611.php
"A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative."
____________________
DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.
Watch More DNews on TestTube http://testtube.com/dnews
Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel
DNews on Twitter http://twitter.com/dnews
Trace Dominguez on Twitter https://twitter.com/tracedominguez
Julia Wilde on Twitter https://twitter.com/julia_sci
DNews on Facebook https://facebook.com/DiscoveryNews
DNews on Google+ http://gplus.to/dnews
Discovery News http://discoverynews.com
Download the TestTube App: http://testu.be/1ndmmMq
https://wn.com/Will_We_Ever_Cure_Hiv
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Twitter: https://twitter.com/jhug00
Read More:
New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine
http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0
"A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday."
HIV vaccine that transforms cell DNA brings fresh hope
http://www.bbc.com/news/health-31511244
"A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report."
Designer protein 'blocks all known strains of HIV'
http://www.medicalnewstoday.com/articles/289611.php
"A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative."
____________________
DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.
Watch More DNews on TestTube http://testtube.com/dnews
Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel
DNews on Twitter http://twitter.com/dnews
Trace Dominguez on Twitter https://twitter.com/tracedominguez
Julia Wilde on Twitter https://twitter.com/julia_sci
DNews on Facebook https://facebook.com/DiscoveryNews
DNews on Google+ http://gplus.to/dnews
Discovery News http://discoverynews.com
Download the TestTube App: http://testu.be/1ndmmMq
- published: 20 Feb 2015
- views: 229018
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
- Order: Reorder
- Duration: 14:11
- Updated: 09 May 2017
- views: 1153
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduat...
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate
degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination
with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in
the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused
on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic
potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his
supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a
group that is steadily expanding, with the aid of new enthusiast medical and doctoral students.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
https://wn.com/The_Forgotten_Virus_(Hiv_2)_|_Mohamed_Mahdi_|_Tedxdebrecenuniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate
degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination
with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in
the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused
on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic
potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his
supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a
group that is steadily expanding, with the aid of new enthusiast medical and doctoral students.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
- published: 09 May 2017
- views: 1153
HIV Vaccine Research : Scientists Finds A Way
- Order: Reorder
- Duration: 1:57
- Updated: 09 Jun 2015
- views: 3700
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodefici...
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus.
Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu
Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU
Social Media Links:
Facebook : https://www.facebook.com/TimesofIndia
Twitter : https://twitter.com/timesofindia
Google + : https://plus.google.com/u/0/+timesindia/posts
'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM
Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd.
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection.
https://wn.com/Hiv_Vaccine_Research_Scientists_Finds_A_Way
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus.
Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu
Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU
Social Media Links:
Facebook : https://www.facebook.com/TimesofIndia
Twitter : https://twitter.com/timesofindia
Google + : https://plus.google.com/u/0/+timesindia/posts
'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM
Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd.
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection.
- published: 09 Jun 2015
- views: 3700
5 People with HIV are now Virus Free - New Vaccine Treatment
- Order: Reorder
- Duration: 1:13
- Updated: 04 Mar 2017
- views: 8430
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to ...
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona.
After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months.
Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART).
Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN.
But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives.
Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”.
“Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent.
Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles.
“The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said.
Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus.
The trial participants continued to take ART for three years, while the researchers monitored their immune responses.
Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant.
The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months.
In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful.
More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust.
https://wn.com/5_People_With_Hiv_Are_Now_Virus_Free_New_Vaccine_Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona.
After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months.
Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART).
Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN.
But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives.
Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”.
“Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent.
Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles.
“The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said.
Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus.
The trial participants continued to take ART for three years, while the researchers monitored their immune responses.
Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant.
The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months.
In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful.
More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust.
- published: 04 Mar 2017
- views: 8430
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
- Order: Reorder
- Duration: 7:29
- Updated: 24 Apr 2014
- views: 2128
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the viru...
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
https://wn.com/Targeting_The_Hiv_Virus_Researchers_Solve_The_Structure_Of_Hiv_1_Capsid_(Improved_Audio)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 24 Apr 2014
- views: 2128
Medical Animation: HIV and AIDS
- Order: Reorder
- Duration: 6:52
- Updated: 25 Nov 2013
- views: 1403229
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium...
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513
This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown.
ANH13111
https://wn.com/Medical_Animation_Hiv_And_Aids
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513
This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown.
ANH13111
- published: 25 Nov 2013
- views: 1403229
HIV Replication 3D Medical Animation
- Order: Reorder
- Duration: 5:14
- Updated: 03 Mar 2007
- views: 1707274
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpain...
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpaint.com/
And other 3D animation videos visit
http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library
Regards,
Dr.Rufus
The Lyrics of this video is here
Targeting HIV replication
The replication of HIV 1 is a multi-stage process.
Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs.
Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte.
Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4.
These receptors interact with protein-complexes, which are embedded in the viral envelope.
These complexes are composed of two glycoproteins:
an extracellular gp 120 and
a transmembrane gp 41
When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment.
It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120.
This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane.
Gp 41 then folds back on itself.
This draws the virus towards the cell and facilitates the fusion of their membranes.
The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes:
Integrase, Protease and Reverse Transcriptase.
Reverse Transcriptase begins the reverse transcription of viral RNA.
It has two catalytic domains:
The Ribonuclease-H active site
And the polymerase active site
Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA.
The polymerase then completes the remaining DNA-strand to form a DNA -- double helix.
Now Integrase goes into action.
It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends.
Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome.
The host cell genome now contains the genetic information of HIV.
Activation of the cell induces transcription of proviral DNA into messenger RNA.
The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised.
Some of them have to be processed by the viral protease.
Protease cleaves longer proteins into smaller core proteins.
This step is crucial to create an infectious virus.
Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid.
This immature particle leaves the cell acquiring a new envelope of host and viral proteins.
The virus matures and becomes ready to infect other cells.
HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression.
Drugs which interfere with the key steps of viral replication can stop this fatal process.
Entry into the host cell can be blocked by fusion inhibitors for example.
Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens.
The action of Integrase can be blocked.
Protease inhibitors are also part of standard antiretroviral therapy.
Each blocked step in viral replication is a step towards better control of HIV disease.
Script, Storyboard, Art Direction by: Frank Schauder, MD
Animation: MACKEVISION
Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS.,
https://wn.com/Hiv_Replication_3D_Medical_Animation
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpaint.com/
And other 3D animation videos visit
http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library
Regards,
Dr.Rufus
The Lyrics of this video is here
Targeting HIV replication
The replication of HIV 1 is a multi-stage process.
Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs.
Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte.
Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4.
These receptors interact with protein-complexes, which are embedded in the viral envelope.
These complexes are composed of two glycoproteins:
an extracellular gp 120 and
a transmembrane gp 41
When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment.
It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120.
This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane.
Gp 41 then folds back on itself.
This draws the virus towards the cell and facilitates the fusion of their membranes.
The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes:
Integrase, Protease and Reverse Transcriptase.
Reverse Transcriptase begins the reverse transcription of viral RNA.
It has two catalytic domains:
The Ribonuclease-H active site
And the polymerase active site
Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA.
The polymerase then completes the remaining DNA-strand to form a DNA -- double helix.
Now Integrase goes into action.
It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends.
Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome.
The host cell genome now contains the genetic information of HIV.
Activation of the cell induces transcription of proviral DNA into messenger RNA.
The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised.
Some of them have to be processed by the viral protease.
Protease cleaves longer proteins into smaller core proteins.
This step is crucial to create an infectious virus.
Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid.
This immature particle leaves the cell acquiring a new envelope of host and viral proteins.
The virus matures and becomes ready to infect other cells.
HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression.
Drugs which interfere with the key steps of viral replication can stop this fatal process.
Entry into the host cell can be blocked by fusion inhibitors for example.
Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens.
The action of Integrase can be blocked.
Protease inhibitors are also part of standard antiretroviral therapy.
Each blocked step in viral replication is a step towards better control of HIV disease.
Script, Storyboard, Art Direction by: Frank Schauder, MD
Animation: MACKEVISION
Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS.,
- published: 03 Mar 2007
- views: 1707274
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
- Order: Reorder
- Duration: 0:45
- Updated: 11 Jul 2017
- views: 143
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating anti...
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity."
http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/
http://www.wochit.com
This video was produced by YT Wochit News using http://wochit.com
https://wn.com/Researchers_Say_Immune_System_May_Prevent_Body_From_Neutralizing_Hiv_Virus
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity."
http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/
http://www.wochit.com
This video was produced by YT Wochit News using http://wochit.com
- published: 11 Jul 2017
- views: 143
-
Researchers successfully eliminate HIV virus from cultured human cells
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple. In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
published: 21 Jul 2014 -
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, ele...
published: 29 May 2013 -
Will We Ever Cure HIV?
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure? Follow Julian on Twitter: https://twitter.com/jhug00 Read More: New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0 "A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday." HIV vaccine that transforms cell DNA brings fresh hope http://www.bbc.com/news/health-31511244 "A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report." Designer protein 'blocks a...
published: 20 Feb 2015 -
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS. Mohamed Mahdi, 37, Sudan After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his supervisor Prof. József Tő...
published: 09 May 2017 -
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU Social Media Links: Facebook : https://www.facebook.com/TimesofIndia Twitter : https://twitter.com/timesofindia Google + : https://plus.google.com/u/0/+timesindia/posts 'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd. Researchers have identified a protein that could help impr...
published: 09 Jun 2015 -
5 People with HIV are now Virus Free - New Vaccine Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona. After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months. Lead scientist Beatriz Mothe said he...
published: 04 Mar 2017 -
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid. The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells. The researchers were able to combine experimental results from Nuclear Magnetic Resonance, ele...
published: 24 Apr 2014 -
Medical Animation: HIV and AIDS
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513 This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown. ANH13111
published: 25 Nov 2013 -
HIV Replication 3D Medical Animation
It is a very excellent animation which explains the hiv replication very clearly. For free download of this video please visit my webpage http://3dmed.wetpaint.com/ And other 3D animation videos visit http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library Regards, Dr.Rufus The Lyrics of this video is here Targeting HIV replication The replication of HIV 1 is a multi-stage process. Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs. Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte. Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4. These receptors interact with protein-co...
published: 03 Mar 2007 -
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity." http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/ http://www.woc...
published: 11 Jul 2017
Researchers successfully eliminate HIV virus from cultured human cells
- Order: Reorder
- Duration: 2:52
- Updated: 21 Jul 2014
- views: 90809
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV...
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple.
In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
https://wn.com/Researchers_Successfully_Eliminate_Hiv_Virus_From_Cultured_Human_Cells
The Temple University School of Medicine research team's approach looks promising as they work towards a permanent cure and potential for protection against HIV. "This is one important step on the path toward a permanent cure for AIDS," says Kamel Khalili, PhD, Professor and Chair of the Department of Neuroscience at Temple.
In a study published on July 21 by the Proceedings of the National Academy of Sciences, Khalili and his colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.
- published: 21 Jul 2014
- views: 90809
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
- Order: Reorder
- Duration: 7:30
- Updated: 29 May 2013
- views: 44360
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the viru...
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
https://wn.com/Targeting_The_Hiv_Virus_Researchers_Use_Supercomputer_To_Solve_The_Structure_Of_The_Hiv_1_Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 29 May 2013
- views: 44360
Will We Ever Cure HIV?
- Order: Reorder
- Duration: 3:48
- Updated: 20 Feb 2015
- views: 229018
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Tw...
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Twitter: https://twitter.com/jhug00
Read More:
New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine
http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0
"A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday."
HIV vaccine that transforms cell DNA brings fresh hope
http://www.bbc.com/news/health-31511244
"A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report."
Designer protein 'blocks all known strains of HIV'
http://www.medicalnewstoday.com/articles/289611.php
"A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative."
____________________
DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.
Watch More DNews on TestTube http://testtube.com/dnews
Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel
DNews on Twitter http://twitter.com/dnews
Trace Dominguez on Twitter https://twitter.com/tracedominguez
Julia Wilde on Twitter https://twitter.com/julia_sci
DNews on Facebook https://facebook.com/DiscoveryNews
DNews on Google+ http://gplus.to/dnews
Discovery News http://discoverynews.com
Download the TestTube App: http://testu.be/1ndmmMq
https://wn.com/Will_We_Ever_Cure_Hiv
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus continues to mutate. Will we ever find a cure?
Follow Julian on Twitter: https://twitter.com/jhug00
Read More:
New Approach to Blocking H.I.V. Raises Hopes for an AIDS Vaccine
http://www.nytimes.com/2015/02/19/health/new-approach-to-blocking-hiv-raises-talk-of-an-aids-vaccine.html?_r=0
"A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday."
HIV vaccine that transforms cell DNA brings fresh hope
http://www.bbc.com/news/health-31511244
"A radical new approach to vaccination seems to completely protect monkeys from HIV, US scientists report."
Designer protein 'blocks all known strains of HIV'
http://www.medicalnewstoday.com/articles/289611.php
"A novel drug candidate against HIV has been created by a joint team led by researchers at The Scripps Research Institute in Jupiter, FL. The scientists consider it to be so potent and effective that it could form the basis of a vaccine alternative."
____________________
DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.
Watch More DNews on TestTube http://testtube.com/dnews
Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel
DNews on Twitter http://twitter.com/dnews
Trace Dominguez on Twitter https://twitter.com/tracedominguez
Julia Wilde on Twitter https://twitter.com/julia_sci
DNews on Facebook https://facebook.com/DiscoveryNews
DNews on Google+ http://gplus.to/dnews
Discovery News http://discoverynews.com
Download the TestTube App: http://testu.be/1ndmmMq
- published: 20 Feb 2015
- views: 229018
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
- Order: Reorder
- Duration: 14:11
- Updated: 09 May 2017
- views: 1153
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduat...
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate
degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination
with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in
the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused
on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic
potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his
supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a
group that is steadily expanding, with the aid of new enthusiast medical and doctoral students.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
https://wn.com/The_Forgotten_Virus_(Hiv_2)_|_Mohamed_Mahdi_|_Tedxdebrecenuniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significance in the race to stop AIDS.
Mohamed Mahdi, 37, Sudan
After graduating as a medical doctor from the University of Debrecen in 2004, he gained a postgraduate
degree in Public Health and Preventive Medicine. After training in infectious diseases, his fascination
with the human immunodeficiency virus led him to pursue a career in academic medicine, particularly in
the field of retroviruses, in which he has currently achieved a PhD degree in HIV. His research is focused
on studying the susceptibility of HIV to antiretroviral drugs, in addition to exploring new therapeutic
potentials that may help tackle the viral infectivity and the long standing AIDS pandemic. Along with his
supervisor Prof. József Tőzsér, he has proudly established a prominent HIV research group in Hungary, a
group that is steadily expanding, with the aid of new enthusiast medical and doctoral students.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
- published: 09 May 2017
- views: 1153
HIV Vaccine Research : Scientists Finds A Way
- Order: Reorder
- Duration: 1:57
- Updated: 09 Jun 2015
- views: 3700
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodefici...
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus.
Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu
Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU
Social Media Links:
Facebook : https://www.facebook.com/TimesofIndia
Twitter : https://twitter.com/timesofindia
Google + : https://plus.google.com/u/0/+timesindia/posts
'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM
Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd.
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection.
https://wn.com/Hiv_Vaccine_Research_Scientists_Finds_A_Way
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus.
Subscribe to Times Of India's Youtube channel here: http://goo.gl/WgIatu
Also Subscribe to Bombay Times Youtube Channel here: http://goo.gl/AdXcgU
Social Media Links:
Facebook : https://www.facebook.com/TimesofIndia
Twitter : https://twitter.com/timesofindia
Google + : https://plus.google.com/u/0/+timesindia/posts
'Download TOI app on Android & iPhone and WIN free recharge coupon worth Rs. 50/- from Paytm - http://goo.gl/AvRYmM
Times Of India's Official YouTube channel is managed by Culture Machine Media Pvt Ltd.
Researchers have identified a protein that could help improve the efficacy of vaccines against human immunodeficiency virus (HIV) and prevent transmission of the virus. A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognise HIV and initiates an immune response to the virus, the results showed. When the protein encounters the virus, it starts a programme that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies. "Vaccines work by teaching the immune system to react by mimicking a natural infection," said a researcher. Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity. "Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection," the researcher added. Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World Health Organisation (WHO). Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection.
- published: 09 Jun 2015
- views: 3700
5 People with HIV are now Virus Free - New Vaccine Treatment
- Order: Reorder
- Duration: 1:13
- Updated: 04 Mar 2017
- views: 8430
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to ...
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona.
After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months.
Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART).
Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN.
But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives.
Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”.
“Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent.
Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles.
“The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said.
Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus.
The trial participants continued to take ART for three years, while the researchers monitored their immune responses.
Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant.
The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months.
In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful.
More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust.
https://wn.com/5_People_With_Hiv_Are_Now_Virus_Free_New_Vaccine_Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. Researchers combined two new HIV vaccines with a drug usually used to treat cancer. A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent Aids without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial, conducted over three years at the IrsiCaixa Aids Research Institute in Barcelona.
After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported the New Scientist. One of them has been drug-free for seven months.
Lead scientist Beatriz Mothe said her team was “on the right path” to developing a treatment which could offer an alternative to daily antiretroviral medication (ART).
Around 18 million people – half of all those living with HIV around the world – take ART to slow the progression of the infection, according to the UN.
But these drugs are expensive and can cause unpleasant side effects. Patients have to remember to take them every day, sometimes over their entire lives.
Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition (Avac), said the study had been carried out on a small scale but its findings were “interesting and important”.
“Long-term systems that don’t require daily pill taking could really help accelerate getting 37 million people with HIV undetectable and not infectious – that would be a great opportunity to turn the tide on the epidemic,” he told The Independent.
Mr Warren said this was an example of a therapeutic vaccine, for people already infected with the disease, as opposed to preventative immunization for diseases such as polio or mumps and measles.
“The idea of a therapeutic vaccine that could provide ongoing control of the virus without having to take a pill every day would be a huge advance,” he said.
Dr. Mothe and her team gave the patients, all recently diagnosed with HIV, two vaccines designed to stimulate the production of white blood cells which can recognize and destroy cells that have been infected by the virus.
The trial participants continued to take ART for three years, while the researchers monitored their immune responses.
Then 15 of the participants received a booster dose of one of the vaccines and a cancer drug called romidepsin, which has been shown to ‘flush out’ the HIV virus from tissues where it can lie dormant.
The virus quickly returned and began to spread again in 10 of these patients, who resumed taking ART, but five of them have maintained suppression of viral load to below the limit of detection for the test, meaning they have not had to take daily drugs for a number of weeks, and in one case for seven months.
In 2015, providing ART to patients in low to middle-income countries cost $19 billion (£15 billion), according to the New Scientist, meaning huge savings could be possible if further research is successful.
More than 100,000 people are living with HIV in the UK, according to the Terrence Higgins Trust.
- published: 04 Mar 2017
- views: 8430
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
- Order: Reorder
- Duration: 7:29
- Updated: 24 Apr 2014
- views: 2128
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the viru...
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
https://wn.com/Targeting_The_Hiv_Virus_Researchers_Solve_The_Structure_Of_Hiv_1_Capsid_(Improved_Audio)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stumbling blocks to creating truly effective therapies to combat the virus is that no one knows the exact structure of the HIV capsid. Until now. Researchers Klaus Schulten and Juan Perilla at the University of Illinois have successfully used the power of one of the fastest supercomputers in the world to create a detailed molecular map of the HIV-1 capsid.
The study offers a first look at the structure of the HIV capsid in 8 Angstrom resolution and offers a basis for research into new pharmacological interventions that could disrupt the capsid function and perhaps derail the virus's ability to infect cells.
The researchers were able to combine experimental results from Nuclear Magnetic Resonance, electron microscopy, and X-ray crystallography and, through molecular dynamics flexible fitting (MDFF) techniques, modeled the capsid using the NSF-funded Blue Waters supercomputer at the National Center for Supercomputing Applications at the University of Illinois.
Schulten is Swanlund Professor of Physics at the University of Illinois at Urbana-Champaign and directs the Theoretical and Computational Biophysics Group at the Beckman Institute. Perilla's research focus is Biophysics and Biophysical Chemistry and he is a Postdoctoral Research Associate in the TCB group at Beckman.
To read the press release about this research, please visit:
http://news.illinois.edu/news/13/0529HIVcapsid_KlausSchulten.html
- published: 24 Apr 2014
- views: 2128
Medical Animation: HIV and AIDS
- Order: Reorder
- Duration: 6:52
- Updated: 25 Nov 2013
- views: 1403229
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium...
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513
This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown.
ANH13111
https://wn.com/Medical_Animation_Hiv_And_Aids
To learn more about licensing this video for content marketing or patient education purposes, visit: http://www.nucleushealth.com/?utm_source=youtube&utm;_medium=video-description&utm;_campaign=hiv-112513
This video, created by Nucleus Medical Media, shows the function of white blood cells in normal immunity. It also portrays how the human immunodeficiency virus (HIV) affects the immune system and causes acquired immunodeficiency syndrome (AIDS). Common types of antiretroviral medications used to treat HIV and AIDS are also shown.
ANH13111
- published: 25 Nov 2013
- views: 1403229
HIV Replication 3D Medical Animation
- Order: Reorder
- Duration: 5:14
- Updated: 03 Mar 2007
- views: 1707274
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpain...
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpaint.com/
And other 3D animation videos visit
http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library
Regards,
Dr.Rufus
The Lyrics of this video is here
Targeting HIV replication
The replication of HIV 1 is a multi-stage process.
Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs.
Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte.
Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4.
These receptors interact with protein-complexes, which are embedded in the viral envelope.
These complexes are composed of two glycoproteins:
an extracellular gp 120 and
a transmembrane gp 41
When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment.
It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120.
This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane.
Gp 41 then folds back on itself.
This draws the virus towards the cell and facilitates the fusion of their membranes.
The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes:
Integrase, Protease and Reverse Transcriptase.
Reverse Transcriptase begins the reverse transcription of viral RNA.
It has two catalytic domains:
The Ribonuclease-H active site
And the polymerase active site
Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA.
The polymerase then completes the remaining DNA-strand to form a DNA -- double helix.
Now Integrase goes into action.
It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends.
Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome.
The host cell genome now contains the genetic information of HIV.
Activation of the cell induces transcription of proviral DNA into messenger RNA.
The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised.
Some of them have to be processed by the viral protease.
Protease cleaves longer proteins into smaller core proteins.
This step is crucial to create an infectious virus.
Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid.
This immature particle leaves the cell acquiring a new envelope of host and viral proteins.
The virus matures and becomes ready to infect other cells.
HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression.
Drugs which interfere with the key steps of viral replication can stop this fatal process.
Entry into the host cell can be blocked by fusion inhibitors for example.
Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens.
The action of Integrase can be blocked.
Protease inhibitors are also part of standard antiretroviral therapy.
Each blocked step in viral replication is a step towards better control of HIV disease.
Script, Storyboard, Art Direction by: Frank Schauder, MD
Animation: MACKEVISION
Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS.,
https://wn.com/Hiv_Replication_3D_Medical_Animation
It is a very excellent animation which explains the hiv replication very clearly.
For free download of this video please visit my webpage
http://3dmed.wetpaint.com/
And other 3D animation videos visit
http://3dmed.wetpaint.com/page/3D+Medical+Animation+Library
Regards,
Dr.Rufus
The Lyrics of this video is here
Targeting HIV replication
The replication of HIV 1 is a multi-stage process.
Each step is crucial to successful replication and is therefore a potential target of antiretroviral drugs.
Step one is the infection of a suitable host-cell, such as a CD4-positive T-lymphocyte.
Entry of HIV into the cell requires the presence of certain receptors on the cell surface, CD4 -- receptors and co-receptors such as CCR5 or CXCR4.
These receptors interact with protein-complexes, which are embedded in the viral envelope.
These complexes are composed of two glycoproteins:
an extracellular gp 120 and
a transmembrane gp 41
When HIV approaches the target cell gp120 binds to the CD4-receptors. This process is termed attachment.
It promotes further binding to a co-receptor. Co-receptor binding results in a conformational change in gp120.
This allows gp41 to unfold and insert its hydrophobic terminus into the cell membrane.
Gp 41 then folds back on itself.
This draws the virus towards the cell and facilitates the fusion of their membranes.
The viral nucleocapsid enters the host cell and breaks open releasing two viral RNA-strands and 3 essential replication enzymes:
Integrase, Protease and Reverse Transcriptase.
Reverse Transcriptase begins the reverse transcription of viral RNA.
It has two catalytic domains:
The Ribonuclease-H active site
And the polymerase active site
Here single stranded viral RNA is transcribed into an RNA-DNA double helix. Ribonuclease- H breaks down the RNA.
The polymerase then completes the remaining DNA-strand to form a DNA -- double helix.
Now Integrase goes into action.
It cleaves a dinucleotide from each 3-prime end of the DNA creating two sticky ends.
Integrase then transfers the DNA into the cell nucleus and facilitates its integration into the host cell genome.
The host cell genome now contains the genetic information of HIV.
Activation of the cell induces transcription of proviral DNA into messenger RNA.
The viral messenger RNA migrates into the cytoplasm where building blocks for a new virus are synthesised.
Some of them have to be processed by the viral protease.
Protease cleaves longer proteins into smaller core proteins.
This step is crucial to create an infectious virus.
Two viral RNA-strands and the replication enzymes then come together and core proteins assemble around them forming the capsid.
This immature particle leaves the cell acquiring a new envelope of host and viral proteins.
The virus matures and becomes ready to infect other cells.
HIV replicates billions of times per day destroying the hosts` immune cells and eventually causing disease progression.
Drugs which interfere with the key steps of viral replication can stop this fatal process.
Entry into the host cell can be blocked by fusion inhibitors for example.
Inhibition of reverse transcriptase by nucleoside inhibitors or by non-nucleoside Reverse Transcriptase- inhibitors is part of standard antiretroviral regimens.
The action of Integrase can be blocked.
Protease inhibitors are also part of standard antiretroviral therapy.
Each blocked step in viral replication is a step towards better control of HIV disease.
Script, Storyboard, Art Direction by: Frank Schauder, MD
Animation: MACKEVISION
Publicity: Dr.Rufus Rajadurai.MD.,D.DiaDENS.,
- published: 03 Mar 2007
- views: 1707274
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
- Order: Reorder
- Duration: 0:45
- Updated: 11 Jul 2017
- views: 143
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating anti...
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity."
http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/
http://www.wochit.com
This video was produced by YT Wochit News using http://wochit.com
https://wn.com/Researchers_Say_Immune_System_May_Prevent_Body_From_Neutralizing_Hiv_Virus
According to a new study from the University of Colorado, the same process that protects the body from autoimmune disease may also prevent it from creating antibodies against HIV-1. The study, published July 11 in the Journal of Experimental Medicine, may point to a possible vaccine that stimulates the production of antibodies to effectively neutralize the HIV-1 virus. Raul M. Torres, professor of immunology and microbiology at the University of Colorado School of Medicine, said in a press release, "We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity."
http://www.upi.com/Health_News/2017/07/11/Immune-system-may-prevent-body-from-neutralizing-HIV-1-researchers-say/2191499797541/
http://www.wochit.com
This video was produced by YT Wochit News using http://wochit.com
- published: 11 Jul 2017
- views: 143
-
Ending the Epidemic: Science Advances on AIDS
This program, Ending the Epidemic: Science Advances on AIDS, brings together leading researchers on the forefront of scientific efforts to understand and attack the virus that causes AIDS. Moderator Richard Besser is joined by pathologist Susan Zolla-Pazner, biologist David Baltimore, activist Peter Staley, and researcher Robert Grant for a conversation about the early 1980s when AIDS was an unknown killer, the challenges activists and researchers faced trying to convince the federal government to fund the science necessary to rein in the epidemic, and what the future holds as the work towards a cure continues. The World Science Festival gathers great minds in science and the arts to produce live and digital content that allows a broad general audience to engage with scientific discover...
published: 03 Dec 2015 -
-
AIDS and the HIV Life Cycle
Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, examines how far our understanding of AIDS has come since the first cases were diagnosed. What causes the immune system to become susceptible to this virus, and how are researchers building on this knowledge to improve drug treatment? Learn more about this virus that has spread across the globe.
published: 03 Nov 2008 -
Peter Duesberg - Inventing The AID$ Virus
a recorded interview on TurnSpeak featuring Dr. Peter Duesberg, author of "Inventing the AIDS Virus." Duesberg discusses what he calls the "conspiracy of self-interest" that keeps the faulty HIV=AIDS hypothesis alive, why Gallo and others could never admit to making a mistake, the scientific reasons why HIV cannot be the cause of AIDS and AIDS is not a contagious disease, the ridiculous logic used in the Kimberly Bergalis/Dr. Acer case, and what happened with Brian Ellison about the publishing of "Inventing The AIDS Virus." Duesberg also gives a fascinating description about how science in America has become totally centralized and "communistic," and a brief discourse on his current research in finding the cause of cancer.
published: 11 Mar 2012 -
Basic Course in HIV - History of HIV | Center for AIDS Research
In conjunction with Brian Zanoni of Harvard Medical School the Harvard University CFAR presents BASIC Course in HIV. BASIC Course in HIV is a basic but comprehensive course on HIV. Please allow 5 seconds for each video to begin playing.
published: 30 Apr 2013 -
Virology 2015 Lecture #24: HIV and AIDS
Some time around 1920 a virus spread from a chimpanzee in Cameroon to a hunter. Over the next 60 years this virus spread through Africa and around the world. It is HIV-1, the cause of 78,000,000 infections and 39,000 deaths. This is the story of that virus.
published: 28 Apr 2015 -
10 scientific arguments why HIV can NOT cause AIDS (dr. Duesberg)
This is a clip from "HIV=AIDS: Fact or Fraud?" (http://www.youtube.com/watch?v=JTxvmKHYajQ). In this clip dr. Duesberg is being interviewed. Dr. Duesberg (full Professor at University of California, Berkeley) is perhaps the best retrovirologist in the world. He discovered the oncogene (the gene that causes cancer) and he decoded for the first the genome of retro-viruses, creating a map that is used by every retro-virologist in the world researching retroviruses. (http://www.youtube.com/watch?v=IfOSKP5zPXs) In this clip 10 scientific arguments are presented why HIV cannot cause AIDS. Arguments/questions that haven't been answered till today. Dr. Duesberg is not alone. Top scientists and Nobel Prize winners agree with him, like: dr. Rasnick, that discovered the protease inhibitors that are ...
published: 14 Nov 2012 -
1982 - 1992 News Clips On HIV/AIDS (The First Ten Years)
RARE CANCER TYPE TRACED TO HOMOSEXUALS 6/17/1982 GAY DISEASE (AIDS) 6/16/1982 DOCTORS SEARCH FOR ANSWERS TO AIDS MYSTERY 6/20/1983 NYC GAY PARADE 6/26/1983 GAY PRIDE DAY CALLS FOR AIDS HELP 6/27/1983 HOUSE OF REPS HEARS TESTIMONY ON AIDS 8/2/1983 GOVERNMENT REPORTS SCIENTIFIC BREAKTHROUGH IN AIDS RESEARCH 4/23/1984 SF PUBLIC HEALTH DEPT CLOSES DOWN BATH HOUSES IN SF TO CURB AIDS EPIDEMIC 10/9/1984 HOUSTON PREPARES TO VOTE ON REFERENDUM ON CIVIL RIGHTS FOR HOMOSEXUALS 1/19/1985 AIDS - PART 4 OF 5 9/12/1985 ACTOR ROCK HUDSON DIES AFTER BATTLE WITH AIDS 10/2/1985 REPORTING OF AIDS CASES LEVELS OFF INDICATING CHANGE IN SEXUAL BEHAVIOR 10/16/1985 AIDS BECOMING POLITICAL ISSUE IN 1986 CAMPAIGNS 10/18/1985 CLOSING OF MINESHAFT GAY BAR AMID AIDS CRISIS 11/6/1985 AIDS JUNKIES 1/20/198...
published: 29 May 2014 -
Vaccines and HIV Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
published: 02 Dec 2008 -
HIV today, gone tomorrow?
Professor Sheena McCormack (Medicine) discusses the trials and tribulations of HIV prevention in her inaugural lecture. Approximately 7,000 people catch HIV every day, twice as many as can be treated using current resources. Sheena McCormack joined the global effort to find new strategies to prevent HIV in 1994, assessing first the potential of a candidate vaccine and then that of candidate vaginal gels. One of these gels, PRO2000/5, progressed through to the last stage of clinical testing, but turned out not to reduce HIV. In 2010, researchers in the field were finally rewarded when two trials revealed that significantly fewer people caught HIV amongst participants taking a drug usually used to treat people who already have the virus. Although the results of later trials have been inco...
published: 30 Oct 2013
Ending the Epidemic: Science Advances on AIDS
- Order: Reorder
- Duration: 1:22:48
- Updated: 03 Dec 2015
- views: 27137
This program, Ending the Epidemic: Science Advances on AIDS, brings together leading researchers on the forefront of scientific efforts to understand and attack...
This program, Ending the Epidemic: Science Advances on AIDS, brings together leading researchers on the forefront of scientific efforts to understand and attack the virus that causes AIDS.
Moderator Richard Besser is joined by pathologist Susan Zolla-Pazner, biologist David Baltimore, activist Peter Staley, and researcher Robert Grant for a conversation about the early 1980s when AIDS was an unknown killer, the challenges activists and researchers faced trying to convince the federal government to fund the science necessary to rein in the epidemic, and what the future holds as the work towards a cure continues.
The World Science Festival gathers great minds in science and the arts to produce live and digital content that allows a broad general audience to engage with scientific discoveries. Our mission is to cultivate a general public informed by science, inspired by its wonder, convinced of its value, and prepared to engage with its implications for the future.
Subscribe to our YouTube Channel for all the latest from WSF.
Visit our Website: http://www.worldsciencefestival.com/
Like us on Facebook: https://www.facebook.com/worldsciencefestival
Follow us on twitter: https://twitter.com/WorldSciFest
Original Program date: May 31, 2013
MODERATOR: Richard Besser
PARTICIPANTS: Susan Zolla-Pazner, David Baltimore, Jean Ashton, Peter Staley, Robert Grant
AIDS: A Timeline 00:04
Richard Besser's Introduction 5:02
Participant Introductions 6:07
What was it like in the early years? 8:03
The non scientific approach to HIV. 15:20
Public stigma and who gets funding. 20:33
What impact did the protests have on the scientific community? 24:45
The Voices of Aids video part 1. 32:47
Finding a vaccine for Aids, why is it so hard? 37:12
What happens when a clinical trial fails? 44:24
Could drug therapy be used to wipe out HIV? 55:13
What does the funding look like for an Aids Drug? 1:01:59
The Voices of Aids video part 2. 1:07:12
Is an end feasible?1:13:46
https://wn.com/Ending_The_Epidemic_Science_Advances_On_Aids
This program, Ending the Epidemic: Science Advances on AIDS, brings together leading researchers on the forefront of scientific efforts to understand and attack the virus that causes AIDS.
Moderator Richard Besser is joined by pathologist Susan Zolla-Pazner, biologist David Baltimore, activist Peter Staley, and researcher Robert Grant for a conversation about the early 1980s when AIDS was an unknown killer, the challenges activists and researchers faced trying to convince the federal government to fund the science necessary to rein in the epidemic, and what the future holds as the work towards a cure continues.
The World Science Festival gathers great minds in science and the arts to produce live and digital content that allows a broad general audience to engage with scientific discoveries. Our mission is to cultivate a general public informed by science, inspired by its wonder, convinced of its value, and prepared to engage with its implications for the future.
Subscribe to our YouTube Channel for all the latest from WSF.
Visit our Website: http://www.worldsciencefestival.com/
Like us on Facebook: https://www.facebook.com/worldsciencefestival
Follow us on twitter: https://twitter.com/WorldSciFest
Original Program date: May 31, 2013
MODERATOR: Richard Besser
PARTICIPANTS: Susan Zolla-Pazner, David Baltimore, Jean Ashton, Peter Staley, Robert Grant
AIDS: A Timeline 00:04
Richard Besser's Introduction 5:02
Participant Introductions 6:07
What was it like in the early years? 8:03
The non scientific approach to HIV. 15:20
Public stigma and who gets funding. 20:33
What impact did the protests have on the scientific community? 24:45
The Voices of Aids video part 1. 32:47
Finding a vaccine for Aids, why is it so hard? 37:12
What happens when a clinical trial fails? 44:24
Could drug therapy be used to wipe out HIV? 55:13
What does the funding look like for an Aids Drug? 1:01:59
The Voices of Aids video part 2. 1:07:12
Is an end feasible?1:13:46
- published: 03 Dec 2015
- views: 27137
The Real Creation Of The HIV/AIDS Virus!
- Order: Reorder
- Duration: 1:29:38
- Updated: 13 Jun 2012
- views: 76255
AIDS and the HIV Life Cycle
- Order: Reorder
- Duration: 59:15
- Updated: 03 Nov 2008
- views: 18218
Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, examines how far our understanding of AIDS has...
Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, examines how far our understanding of AIDS has come since the first cases were diagnosed. What causes the immune system to become susceptible to this virus, and how are researchers building on this knowledge to improve drug treatment? Learn more about this virus that has spread across the globe.
https://wn.com/Aids_And_The_Hiv_Life_Cycle
Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, examines how far our understanding of AIDS has come since the first cases were diagnosed. What causes the immune system to become susceptible to this virus, and how are researchers building on this knowledge to improve drug treatment? Learn more about this virus that has spread across the globe.
- published: 03 Nov 2008
- views: 18218
Peter Duesberg - Inventing The AID$ Virus
- Order: Reorder
- Duration: 44:30
- Updated: 11 Mar 2012
- views: 5496
a recorded interview on TurnSpeak featuring Dr. Peter Duesberg, author of "Inventing the AIDS Virus." Duesberg discusses what he calls the "conspiracy of self-i...
a recorded interview on TurnSpeak featuring Dr. Peter Duesberg, author of "Inventing the AIDS Virus." Duesberg discusses what he calls the "conspiracy of self-interest" that keeps the faulty HIV=AIDS hypothesis alive, why Gallo and others could never admit to making a mistake, the scientific reasons why HIV cannot be the cause of AIDS and AIDS is not a contagious disease, the ridiculous logic used in the Kimberly Bergalis/Dr. Acer case, and what happened with Brian Ellison about the publishing of "Inventing The AIDS Virus." Duesberg also gives a fascinating description about how science in America has become totally centralized and "communistic," and a brief discourse on his current research in finding the cause of cancer.
https://wn.com/Peter_Duesberg_Inventing_The_Aid_Virus
a recorded interview on TurnSpeak featuring Dr. Peter Duesberg, author of "Inventing the AIDS Virus." Duesberg discusses what he calls the "conspiracy of self-interest" that keeps the faulty HIV=AIDS hypothesis alive, why Gallo and others could never admit to making a mistake, the scientific reasons why HIV cannot be the cause of AIDS and AIDS is not a contagious disease, the ridiculous logic used in the Kimberly Bergalis/Dr. Acer case, and what happened with Brian Ellison about the publishing of "Inventing The AIDS Virus." Duesberg also gives a fascinating description about how science in America has become totally centralized and "communistic," and a brief discourse on his current research in finding the cause of cancer.
- published: 11 Mar 2012
- views: 5496
Basic Course in HIV - History of HIV | Center for AIDS Research
- Order: Reorder
- Duration: 1:01:04
- Updated: 30 Apr 2013
- views: 10318
In conjunction with Brian Zanoni of Harvard Medical School the Harvard University CFAR presents BASIC Course in HIV. BASIC Course in HIV is a basic but comprehe...
In conjunction with Brian Zanoni of Harvard Medical School the Harvard University CFAR presents BASIC Course in HIV. BASIC Course in HIV is a basic but comprehensive course on HIV. Please allow 5 seconds for each video to begin playing.
https://wn.com/Basic_Course_In_Hiv_History_Of_Hiv_|_Center_For_Aids_Research
In conjunction with Brian Zanoni of Harvard Medical School the Harvard University CFAR presents BASIC Course in HIV. BASIC Course in HIV is a basic but comprehensive course on HIV. Please allow 5 seconds for each video to begin playing.
- published: 30 Apr 2013
- views: 10318
Virology 2015 Lecture #24: HIV and AIDS
- Order: Reorder
- Duration: 1:14:32
- Updated: 28 Apr 2015
- views: 6471
Some time around 1920 a virus spread from a chimpanzee in Cameroon to a hunter. Over the next 60 years this virus spread through Africa and around the world. It...
Some time around 1920 a virus spread from a chimpanzee in Cameroon to a hunter. Over the next 60 years this virus spread through Africa and around the world. It is HIV-1, the cause of 78,000,000 infections and 39,000 deaths. This is the story of that virus.
https://wn.com/Virology_2015_Lecture_24_Hiv_And_Aids
10 scientific arguments why HIV can NOT cause AIDS (dr. Duesberg)
- Order: Reorder
- Duration: 29:59
- Updated: 14 Nov 2012
- views: 101833
This is a clip from "HIV=AIDS: Fact or Fraud?" (http://www.youtube.com/watch?v=JTxvmKHYajQ). In this clip dr. Duesberg is being interviewed. Dr. Duesberg (full ...
This is a clip from "HIV=AIDS: Fact or Fraud?" (http://www.youtube.com/watch?v=JTxvmKHYajQ). In this clip dr. Duesberg is being interviewed. Dr. Duesberg (full Professor at University of California, Berkeley) is perhaps the best retrovirologist in the world. He discovered the oncogene (the gene that causes cancer) and he decoded for the first the genome of retro-viruses, creating a map that is used by every retro-virologist in the world researching retroviruses. (http://www.youtube.com/watch?v=IfOSKP5zPXs)
In this clip 10 scientific arguments are presented why HIV cannot cause AIDS. Arguments/questions that haven't been answered till today. Dr. Duesberg is not alone. Top scientists and Nobel Prize winners agree with him, like: dr. Rasnick, that discovered the protease inhibitors that are being used as HIV drugs. Dr Mullis a nobel prize winner, invented the PCR, the method being used to detect viruses (including HIV). Richard Strohman, professor at the department of Cell Biology in University of California, Berkeley. Nobel prize winner dr. Walter Gilbert from Harvard University and dr. Charles Thomas, a Molecular Biologist and former Professor of Biochemistry at Harvard University.
Those scientists claim that whoever doesn't support the hypothesis that HIV causes AIDS gets no funding for his research, so young scientists don't even dare to oppose the HIV=AIDS hypothesis anymore. Dr Duesberg even calls them "prostitutes".
https://wn.com/10_Scientific_Arguments_Why_Hiv_Can_Not_Cause_Aids_(Dr._Duesberg)
This is a clip from "HIV=AIDS: Fact or Fraud?" (http://www.youtube.com/watch?v=JTxvmKHYajQ). In this clip dr. Duesberg is being interviewed. Dr. Duesberg (full Professor at University of California, Berkeley) is perhaps the best retrovirologist in the world. He discovered the oncogene (the gene that causes cancer) and he decoded for the first the genome of retro-viruses, creating a map that is used by every retro-virologist in the world researching retroviruses. (http://www.youtube.com/watch?v=IfOSKP5zPXs)
In this clip 10 scientific arguments are presented why HIV cannot cause AIDS. Arguments/questions that haven't been answered till today. Dr. Duesberg is not alone. Top scientists and Nobel Prize winners agree with him, like: dr. Rasnick, that discovered the protease inhibitors that are being used as HIV drugs. Dr Mullis a nobel prize winner, invented the PCR, the method being used to detect viruses (including HIV). Richard Strohman, professor at the department of Cell Biology in University of California, Berkeley. Nobel prize winner dr. Walter Gilbert from Harvard University and dr. Charles Thomas, a Molecular Biologist and former Professor of Biochemistry at Harvard University.
Those scientists claim that whoever doesn't support the hypothesis that HIV causes AIDS gets no funding for his research, so young scientists don't even dare to oppose the HIV=AIDS hypothesis anymore. Dr Duesberg even calls them "prostitutes".
- published: 14 Nov 2012
- views: 101833
1982 - 1992 News Clips On HIV/AIDS (The First Ten Years)
- Order: Reorder
- Duration: 56:12
- Updated: 29 May 2014
- views: 165141
RARE CANCER TYPE TRACED TO HOMOSEXUALS 6/17/1982
GAY DISEASE (AIDS) 6/16/1982
DOCTORS SEARCH FOR ANSWERS TO AIDS MYSTERY 6/20/1983
NYC GAY PARADE 6/26/1983
...
RARE CANCER TYPE TRACED TO HOMOSEXUALS 6/17/1982
GAY DISEASE (AIDS) 6/16/1982
DOCTORS SEARCH FOR ANSWERS TO AIDS MYSTERY 6/20/1983
NYC GAY PARADE 6/26/1983
GAY PRIDE DAY CALLS FOR AIDS HELP 6/27/1983
HOUSE OF REPS HEARS TESTIMONY ON AIDS 8/2/1983
GOVERNMENT REPORTS SCIENTIFIC BREAKTHROUGH IN AIDS RESEARCH 4/23/1984
SF PUBLIC HEALTH DEPT CLOSES DOWN BATH HOUSES IN SF TO CURB AIDS EPIDEMIC 10/9/1984
HOUSTON PREPARES TO VOTE ON REFERENDUM ON CIVIL RIGHTS FOR HOMOSEXUALS 1/19/1985
AIDS - PART 4 OF 5 9/12/1985
ACTOR ROCK HUDSON DIES AFTER BATTLE WITH AIDS 10/2/1985
REPORTING OF AIDS CASES LEVELS OFF INDICATING CHANGE IN SEXUAL BEHAVIOR 10/16/1985
AIDS BECOMING POLITICAL ISSUE IN 1986 CAMPAIGNS 10/18/1985
CLOSING OF MINESHAFT GAY BAR AMID AIDS CRISIS 11/6/1985
AIDS JUNKIES 1/20/1986
KOKOMO PARENTS SEEK TO BLOCK AIDS BOY FROM RETURNING TO CLASS 2/20/1986
RYAN WHITE ARRIVES FOR FIRST DAY OF SCHOOL 8/26/1986
RYAN WHITE DIES AT 18 THE VICTIM OF AIDS 4/8/1990
SCOTUS TO DETERMINE STATES RIGHTS ON LEGISLATIVE RESTRICTIONS ON GAY ACTS 3/31/1986
JUSTICE DEPT RULES EMPLOYERS CAN FIRE AIDS VICTIMS TO PREVENT AIDS SPREADING 6/23/1986
ULTRA-RIGHT WINGER LYNDON LAROUCHE ASKS FOR QUARANTINE OF AIDS VICTIMS 6/25/1986
THE FIRST HOSPITAL DEVOTED TO AIDS TREATMENT : RESEARCH OPENS IN TEXAS 8/27/1986
CONTROVERSY CONTINUES OVER PROP 64 WHICH WOULD QUARANTINE AIDS PATIENTS 9/16/1986
FEDERAL GOVERNMENT APPROVES SALE OF AZT IN PRESCRIPTION FORM 3/20/1987
PRES REAGAN URGES YOUTH TO ABSTAIN FROM SEX TO AVOID AIDS 4/1/1987
COL LEGISLATURE CONSIDERS BILL REQUIRING DRs TO REPORT NAMES OF HIV POSITIVE 4/22/1987
REAGAN ADMINS LONG RANGE PLANS FOR AIDS INCLUDE MANDATORY TESTING 5/28/1987
REAGAN ADMINISTRATION SPEAKS OUT ON TOPIC OF AIDS TESTING 6/1/1987
PRES REAGAN NAMES NATIONAL COMMISSION ON AIDS : INCLUDES GAY ACTIVIST 7/23/1987
FRONT PAGE: GAY MARCH CONTENDS WITH AIDS ISSUE 10/11/1987
WASHINGTON GAY MARCH 10/11/1987
GAYS PROTEST OUTSIDE SCOTUS OVER LACK OF AIDS FUNDING 10/13/1987
AIDS PROTEST IN NYC 3/24/1988
STONEWALL:GAY PARADE NATSOT MATERIAL 6/25/1989
GAY LIB DEMONSTRATORS CELEBRATE TWENTY YEARS OUT OF THE CLOSET 6/25/1989
AZT TESTING GIVES NEW HOPE TO AIDS PATIENTS 8/18/1989
AFTER EIGHT: AIDS MILITANTS (INTERVIEW WITH LARRY KRAMER) 3/20/1990
AIDS IN THE 90s 3/27/1990
MAGIC JOHNSON PRESS CONFERENCE RE: TESTING POSITIVE FOR AIDS VIRUS 11/7/1991
AIDS CONFERENCE IN FLORENCE WILL FOCUS ON EXPLOSION OF EPIDEMIC IN AFRICA 6/16/1991
AIDS IS SPREADING THROUGH DEVELOPING COUNTRIES 6/17/1991
AIDS QUILT UNFURLED IN WASHINGTON 10/10/1992
https://wn.com/1982_1992_News_Clips_On_Hiv_Aids_(The_First_Ten_Years)
RARE CANCER TYPE TRACED TO HOMOSEXUALS 6/17/1982
GAY DISEASE (AIDS) 6/16/1982
DOCTORS SEARCH FOR ANSWERS TO AIDS MYSTERY 6/20/1983
NYC GAY PARADE 6/26/1983
GAY PRIDE DAY CALLS FOR AIDS HELP 6/27/1983
HOUSE OF REPS HEARS TESTIMONY ON AIDS 8/2/1983
GOVERNMENT REPORTS SCIENTIFIC BREAKTHROUGH IN AIDS RESEARCH 4/23/1984
SF PUBLIC HEALTH DEPT CLOSES DOWN BATH HOUSES IN SF TO CURB AIDS EPIDEMIC 10/9/1984
HOUSTON PREPARES TO VOTE ON REFERENDUM ON CIVIL RIGHTS FOR HOMOSEXUALS 1/19/1985
AIDS - PART 4 OF 5 9/12/1985
ACTOR ROCK HUDSON DIES AFTER BATTLE WITH AIDS 10/2/1985
REPORTING OF AIDS CASES LEVELS OFF INDICATING CHANGE IN SEXUAL BEHAVIOR 10/16/1985
AIDS BECOMING POLITICAL ISSUE IN 1986 CAMPAIGNS 10/18/1985
CLOSING OF MINESHAFT GAY BAR AMID AIDS CRISIS 11/6/1985
AIDS JUNKIES 1/20/1986
KOKOMO PARENTS SEEK TO BLOCK AIDS BOY FROM RETURNING TO CLASS 2/20/1986
RYAN WHITE ARRIVES FOR FIRST DAY OF SCHOOL 8/26/1986
RYAN WHITE DIES AT 18 THE VICTIM OF AIDS 4/8/1990
SCOTUS TO DETERMINE STATES RIGHTS ON LEGISLATIVE RESTRICTIONS ON GAY ACTS 3/31/1986
JUSTICE DEPT RULES EMPLOYERS CAN FIRE AIDS VICTIMS TO PREVENT AIDS SPREADING 6/23/1986
ULTRA-RIGHT WINGER LYNDON LAROUCHE ASKS FOR QUARANTINE OF AIDS VICTIMS 6/25/1986
THE FIRST HOSPITAL DEVOTED TO AIDS TREATMENT : RESEARCH OPENS IN TEXAS 8/27/1986
CONTROVERSY CONTINUES OVER PROP 64 WHICH WOULD QUARANTINE AIDS PATIENTS 9/16/1986
FEDERAL GOVERNMENT APPROVES SALE OF AZT IN PRESCRIPTION FORM 3/20/1987
PRES REAGAN URGES YOUTH TO ABSTAIN FROM SEX TO AVOID AIDS 4/1/1987
COL LEGISLATURE CONSIDERS BILL REQUIRING DRs TO REPORT NAMES OF HIV POSITIVE 4/22/1987
REAGAN ADMINS LONG RANGE PLANS FOR AIDS INCLUDE MANDATORY TESTING 5/28/1987
REAGAN ADMINISTRATION SPEAKS OUT ON TOPIC OF AIDS TESTING 6/1/1987
PRES REAGAN NAMES NATIONAL COMMISSION ON AIDS : INCLUDES GAY ACTIVIST 7/23/1987
FRONT PAGE: GAY MARCH CONTENDS WITH AIDS ISSUE 10/11/1987
WASHINGTON GAY MARCH 10/11/1987
GAYS PROTEST OUTSIDE SCOTUS OVER LACK OF AIDS FUNDING 10/13/1987
AIDS PROTEST IN NYC 3/24/1988
STONEWALL:GAY PARADE NATSOT MATERIAL 6/25/1989
GAY LIB DEMONSTRATORS CELEBRATE TWENTY YEARS OUT OF THE CLOSET 6/25/1989
AZT TESTING GIVES NEW HOPE TO AIDS PATIENTS 8/18/1989
AFTER EIGHT: AIDS MILITANTS (INTERVIEW WITH LARRY KRAMER) 3/20/1990
AIDS IN THE 90s 3/27/1990
MAGIC JOHNSON PRESS CONFERENCE RE: TESTING POSITIVE FOR AIDS VIRUS 11/7/1991
AIDS CONFERENCE IN FLORENCE WILL FOCUS ON EXPLOSION OF EPIDEMIC IN AFRICA 6/16/1991
AIDS IS SPREADING THROUGH DEVELOPING COUNTRIES 6/17/1991
AIDS QUILT UNFURLED IN WASHINGTON 10/10/1992
- published: 29 May 2014
- views: 165141
Vaccines and HIV Evolution
- Order: Reorder
- Duration: 59:09
- Updated: 02 Dec 2008
- views: 4540
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to...
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
https://wn.com/Vaccines_And_Hiv_Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
- published: 02 Dec 2008
- views: 4540
HIV today, gone tomorrow?
- Order: Reorder
- Duration: 1:13:24
- Updated: 30 Oct 2013
- views: 4417
Professor Sheena McCormack (Medicine) discusses the trials and tribulations of HIV prevention in her inaugural lecture.
Approximately 7,000 people catch HIV ev...
Professor Sheena McCormack (Medicine) discusses the trials and tribulations of HIV prevention in her inaugural lecture.
Approximately 7,000 people catch HIV every day, twice as many as can be treated using current resources.
Sheena McCormack joined the global effort to find new strategies to prevent HIV in 1994, assessing first the potential of a candidate vaccine and then that of candidate vaginal gels. One of these gels, PRO2000/5, progressed through to the last stage of clinical testing, but turned out not to reduce HIV.
In 2010, researchers in the field were finally rewarded when two trials revealed that significantly fewer people caught HIV amongst participants taking a drug usually used to treat people who already have the virus. Although the results of later trials have been inconsistent, there was enough evidence for the US drug authorities to licence Truvada as a daily pre-exposure prophylaxis (PrEP) in 2012.
The priority now is to promote HIV testing and embrace the range of proven strategies to reduce HIV, whilst continuing the search for new methods including a vaccine.
For more information please visit http://bit.ly/17YVq8R
https://wn.com/Hiv_Today,_Gone_Tomorrow
Professor Sheena McCormack (Medicine) discusses the trials and tribulations of HIV prevention in her inaugural lecture.
Approximately 7,000 people catch HIV every day, twice as many as can be treated using current resources.
Sheena McCormack joined the global effort to find new strategies to prevent HIV in 1994, assessing first the potential of a candidate vaccine and then that of candidate vaginal gels. One of these gels, PRO2000/5, progressed through to the last stage of clinical testing, but turned out not to reduce HIV.
In 2010, researchers in the field were finally rewarded when two trials revealed that significantly fewer people caught HIV amongst participants taking a drug usually used to treat people who already have the virus. Although the results of later trials have been inconsistent, there was enough evidence for the US drug authorities to licence Truvada as a daily pre-exposure prophylaxis (PrEP) in 2012.
The priority now is to promote HIV testing and embrace the range of proven strategies to reduce HIV, whilst continuing the search for new methods including a vaccine.
For more information please visit http://bit.ly/17YVq8R
- published: 30 Oct 2013
- views: 4417
- Playlist
- Chat
2:52
Researchers successfully eliminate HIV virus from cultured human cells
The Temple University School of Medicine research team's approach looks promising as they ...
published: 21 Jul 2014
Researchers successfully eliminate HIV virus from cultured human cells
Researchers successfully eliminate HIV virus from cultured human cells
- Report rights infringement
- published: 21 Jul 2014
- views: 90809
7:30
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stu...
published: 29 May 2013
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
- Report rights infringement
- published: 29 May 2013
- views: 44360
3:48
Will We Ever Cure HIV?
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus...
published: 20 Feb 2015
Will We Ever Cure HIV?
Will We Ever Cure HIV?
- Report rights infringement
- published: 20 Feb 2015
- views: 229018
14:11
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significa...
published: 09 May 2017
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
- Report rights infringement
- published: 09 May 2017
- views: 1153
1:57
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that ...
published: 09 Jun 2015
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way
- Report rights infringement
- published: 09 Jun 2015
- views: 3700
1:13
5 People with HIV are now Virus Free - New Vaccine Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. ...
published: 04 Mar 2017
5 People with HIV are now Virus Free - New Vaccine Treatment
5 People with HIV are now Virus Free - New Vaccine Treatment
- Report rights infringement
- published: 04 Mar 2017
- views: 8430
7:29
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stu...
published: 24 Apr 2014
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
- Report rights infringement
- published: 24 Apr 2014
- views: 2128
6:52
Medical Animation: HIV and AIDS
To learn more about licensing this video for content marketing or patient education purpos...
published: 25 Nov 2013
Medical Animation: HIV and AIDS
Medical Animation: HIV and AIDS
- Report rights infringement
- published: 25 Nov 2013
- views: 1403229
5:14
HIV Replication 3D Medical Animation
It is a very excellent animation which explains the hiv replication very clearly.
For fre...
published: 03 Mar 2007
HIV Replication 3D Medical Animation
HIV Replication 3D Medical Animation
- Report rights infringement
- published: 03 Mar 2007
- views: 1707274
0:45
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
According to a new study from the University of Colorado, the same process that protects t...
published: 11 Jul 2017
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
- Report rights infringement
- published: 11 Jul 2017
- views: 143
- Playlist
- Chat
2:52
Researchers successfully eliminate HIV virus from cultured human cells
The Temple University School of Medicine research team's approach looks promising as they ...
published: 21 Jul 2014
Researchers successfully eliminate HIV virus from cultured human cells
Researchers successfully eliminate HIV virus from cultured human cells
- Report rights infringement
- published: 21 Jul 2014
- views: 90809
7:30
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stu...
published: 29 May 2013
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
Targeting the HIV Virus: Researchers Use Supercomputer to Solve the Structure of the HIV-1 Capsid
- Report rights infringement
- published: 29 May 2013
- views: 44360
3:48
Will We Ever Cure HIV?
Researchers believe that they might have a developed a vaccine to treat HIV, but the virus...
published: 20 Feb 2015
Will We Ever Cure HIV?
Will We Ever Cure HIV?
- Report rights infringement
- published: 20 Feb 2015
- views: 229018
14:11
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
In his TEDx talk, Dr. Mahdi will introduce this lesser known type of HIV and its significa...
published: 09 May 2017
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
The Forgotten Virus (HIV-2) | Mohamed Mahdi | TEDxDebrecenUniversity
- Report rights infringement
- published: 09 May 2017
- views: 1153
1:57
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way
Researchers have identified a protein that ...
published: 09 Jun 2015
HIV Vaccine Research : Scientists Finds A Way
HIV Vaccine Research : Scientists Finds A Way
- Report rights infringement
- published: 09 Jun 2015
- views: 3700
1:13
5 People with HIV are now Virus Free - New Vaccine Treatment
Five HIV patients left 'virus-free' with no need for daily drugs in early vaccine trials. ...
published: 04 Mar 2017
5 People with HIV are now Virus Free - New Vaccine Treatment
5 People with HIV are now Virus Free - New Vaccine Treatment
- Report rights infringement
- published: 04 Mar 2017
- views: 8430
7:29
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
The HIV virus is housed inside a protective shell called a capsid. One of the biggest stu...
published: 24 Apr 2014
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
Targeting the HIV Virus: Researchers Solve the Structure of HIV-1 Capsid (IMPROVED AUDIO)
- Report rights infringement
- published: 24 Apr 2014
- views: 2128
6:52
Medical Animation: HIV and AIDS
To learn more about licensing this video for content marketing or patient education purpos...
published: 25 Nov 2013
Medical Animation: HIV and AIDS
Medical Animation: HIV and AIDS
- Report rights infringement
- published: 25 Nov 2013
- views: 1403229
5:14
HIV Replication 3D Medical Animation
It is a very excellent animation which explains the hiv replication very clearly.
For fre...
published: 03 Mar 2007
HIV Replication 3D Medical Animation
HIV Replication 3D Medical Animation
- Report rights infringement
- published: 03 Mar 2007
- views: 1707274
0:45
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
According to a new study from the University of Colorado, the same process that protects t...
published: 11 Jul 2017
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
Researchers Say Immune System May Prevent Body From Neutralizing HIV Virus
- Report rights infringement
- published: 11 Jul 2017
- views: 143
- Playlist
- Chat
1:22:48
Ending the Epidemic: Science Advances on AIDS
This program, Ending the Epidemic: Science Advances on AIDS, brings together leading resea...
published: 03 Dec 2015
Ending the Epidemic: Science Advances on AIDS
Ending the Epidemic: Science Advances on AIDS
- Report rights infringement
- published: 03 Dec 2015
- views: 27137
1:29:38
The Real Creation Of The HIV/AIDS Virus!
Where & How HIV/AIDS Began.
published: 13 Jun 2012
The Real Creation Of The HIV/AIDS Virus!
The Real Creation Of The HIV/AIDS Virus!
- Report rights infringement
- published: 13 Jun 2012
- views: 76255
59:15
AIDS and the HIV Life Cycle
Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Ce...
published: 03 Nov 2008
AIDS and the HIV Life Cycle
AIDS and the HIV Life Cycle
- Report rights infringement
- published: 03 Nov 2008
- views: 18218
44:30
Peter Duesberg - Inventing The AID$ Virus
a recorded interview on TurnSpeak featuring Dr. Peter Duesberg, author of "Inventing the A...
published: 11 Mar 2012
Peter Duesberg - Inventing The AID$ Virus
Peter Duesberg - Inventing The AID$ Virus
- Report rights infringement
- published: 11 Mar 2012
- views: 5496
1:01:04
Basic Course in HIV - History of HIV | Center for AIDS Research
In conjunction with Brian Zanoni of Harvard Medical School the Harvard University CFAR pre...
published: 30 Apr 2013
Basic Course in HIV - History of HIV | Center for AIDS Research
Basic Course in HIV - History of HIV | Center for AIDS Research
- Report rights infringement
- published: 30 Apr 2013
- views: 10318
1:14:32
Virology 2015 Lecture #24: HIV and AIDS
Some time around 1920 a virus spread from a chimpanzee in Cameroon to a hunter. Over the n...
published: 28 Apr 2015
Virology 2015 Lecture #24: HIV and AIDS
Virology 2015 Lecture #24: HIV and AIDS
- Report rights infringement
- published: 28 Apr 2015
- views: 6471
29:59
10 scientific arguments why HIV can NOT cause AIDS (dr. Duesberg)
This is a clip from "HIV=AIDS: Fact or Fraud?" (http://www.youtube.com/watch?v=JTxvmKHYajQ...
published: 14 Nov 2012
10 scientific arguments why HIV can NOT cause AIDS (dr. Duesberg)
10 scientific arguments why HIV can NOT cause AIDS (dr. Duesberg)
- Report rights infringement
- published: 14 Nov 2012
- views: 101833
56:12
1982 - 1992 News Clips On HIV/AIDS (The First Ten Years)
RARE CANCER TYPE TRACED TO HOMOSEXUALS 6/17/1982
GAY DISEASE (AIDS) 6/16/1982
DOCTORS SE...
published: 29 May 2014
1982 - 1992 News Clips On HIV/AIDS (The First Ten Years)
1982 - 1992 News Clips On HIV/AIDS (The First Ten Years)
- Report rights infringement
- published: 29 May 2014
- views: 165141
59:09
Vaccines and HIV Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institu...
published: 02 Dec 2008
Vaccines and HIV Evolution
Vaccines and HIV Evolution
- Report rights infringement
- published: 02 Dec 2008
- views: 4540
1:13:24
HIV today, gone tomorrow?
Professor Sheena McCormack (Medicine) discusses the trials and tribulations of HIV prevent...
published: 30 Oct 2013
HIV today, gone tomorrow?
HIV today, gone tomorrow?
- Report rights infringement
- published: 30 Oct 2013
- views: 4417
Ending the Epidemic: Science Advances on AIDS...
The Real Creation Of The HIV/AIDS Virus!...
AIDS and the HIV Life Cycle...
Peter Duesberg - Inventing The AID$ Virus...
Basic Course in HIV - History of HIV | Center for ...
Virology 2015 Lecture #24: HIV and AIDS...
10 scientific arguments why HIV can NOT cause AIDS...
1982 - 1992 News Clips On HIV/AIDS (The First Ten ...
Vaccines and HIV Evolution...
HIV today, gone tomorrow?...
See more photos of aids virus research
back
'Never been about race': black activists on how Minneapolis reacted to Damond shooting
Edit The Guardian 22 Jul 2017
Some questioned whether activists had protested less over the death of a White Australian woman. Friday night’s anger at mayor Betsy Hodges and the departure of the city’s police chief answered that. Justine Damond shooting. 'Never been about race'. black activists on how Minneapolis reacted to Damond shooting. Some questioned whether activists had protested less over the death of a White Australian woman ... “Where are the protests now?” ... ....
back
Hackers access millions of Social Security numbers, 10 states affected
Edit Russia Today 22 Jul 2017
A security breach in the Kansas Department of Commerce has exposed millions of Social Security numbers from people across 10 states to hackers. Many other accounts were also attacked ... ....
back
Kushner discloses additional $10M in assets
Edit Times Free Press 22 Jul 2017
WASHINGTON (AP) - President Donald Trump's son-in-law and senior adviser Jared Kushner "inadvertently omitted" more than 70 assets worth at least $10.6 million from his personal financial disclosure reports, according to revised paperwork released Friday. The previously unreported assets were included in updated disclosure reports certified by the U.S ... ___ ... Researcher Jennifer Farrar in New York contributed to this report. ....
back
Teens Who Taunted, Filmed Drowning Man Won't Be Charged In His Death
Edit WorldNews.com 21 Jul 2017
At one point, one of the teen boys can be heard laughing, saying "he dead."The state of Florida currently does not have a law where a citizen is obligated to render aid or call for help for anyone in distress."If there was (a law like that) we would charge them," Cocoa Police Department spokeswoman Yvonne Martinez told CNN by phone."The family is frustrated ... No one deserves to go like that."...
back
Minneapolis shooting brings unwelcome attention to Somalis
Edit Post-Bulletin 22 Jul 2017
MINNEAPOLIS (AP) — The killing of an unarmed Australian woman by a Minneapolis police officer who is a Somali-American has turned an unwelcome spotlight on the city's beleaguered Somali community, where many again find themselves on the defensive ... But negative comments have included former U.S. Rep ... Bachmann also suggested Noor may have shot Damond for "cultural" reasons ... "This is about an individual officer's actions ... city council ... ——— ... ....
Man who bit, spit on officers at Riverwalk accused of 'intentional exposure to AIDS'
Edit The Times Picayune 22 Jul 2017
disturbing the peace, two counts of resisting arrest and two counts of "attempted intentional exposure to AIDS Virus." ... MarkAlain Dery, the medical director of the Tulane T-Cell Clinic in Mid-City and director of Tulane's AIDS Education and Training Center, said Louisiana's law making "intentional exposure to the AIDS Virus" a crime is "grossly outdated."....
Policy to curb spread of AIDS reinforced
Edit Manila Standard Today 22 Jul 2017
The House of Representatives’ committee on health has approved a substitute bill seeking to strengthen the country’s policy to prevent the growing prevalence of Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome cases ... House of Representatives , committee on health , comprehensive policy , Human Immunodeficiency Virus , HIV , Acquired Immune Deficiency Syndrome , AIDS ,....
Tackling HIV In Prisons
Edit Peace FM Online 22 Jul 2017
In some way, he had prison to thank because it was in prison that he was first diagnosed and treated, but unsurprisingly, the care he received as a prisoner with AIDs was somewhat lacking ... Though records available indicate that most of the inmates with HIV were affected before they entered into the prison, incarceration offers ample opportunities to spread the virus ... Screening Of The Virus In Prisons....
HIV and cancer teams double up to seek out new disease killers
Edit Yahoo Daily News 22 Jul 2017
Sharon Lewin, an HIV expert at the University of Melbourne and co-chair of the IAS's HIV Cure and Cancer forum, describes this progress in oncology as a "revolution" which has led to "some spectacular successes" that are now being eyed by AIDS researchers ... While HIV researchers are keen to see whether new-generation cancer drugs could show promise ......
Ask Dr Bruce Chard: Is my cat at risk from playing with the neighbour's cat
Edit Stuff 22 Jul 2017
Phoebe, our 6-year-old Ragdoll cat often plays with a neighbour's cat that does not appear to be well looked after as she has a matted coat ... Make sure Phoebe is up to date with regular vaccinations that guard against enteritis and respiratory viruses that cause cold-like symptoms. It is unlikely there is a risk of her catching the cat Aids-type virus as this is spread by bites and that is unlikely if they just play ... READ MORE.....
That dreaded disease called distemper
Edit Manila Standard Today 22 Jul 2017
THE VIRUS. WebMD describes distemper as “a virus that affects a dog’s respiratory, gastrointestinal, and central nervous system, as well as the conjunctival membranes of the eye.” Blossom, a dog pulled out by Save Animals of Love and Light (Save ALL) from the Cainta pound in 2014, survived distemper and has been adopted by Dodie Garcia-Cu ... Sneezing and coughing by infected animals are ways the virus can be passed on....
First West Nile virus death this season in Maricopa County
Edit The Oklahoman 22 Jul 2017
PHOENIX (AP) — Officials in Maricopa County say they've recorded the first West Nile virus death....
Pale Rider by Laura Spinney review – the flu pandemic that killed 50 million
Edit The Guardian 22 Jul 2017
Vanished until 2005, the H1N1 strain of the influenza virus was brought back to life for the purpose of better understanding its catastrophic effect on the world’s population a century ago ... We now know that the flu virus is a parasite that needs the host cell of another living organism in order to reproduce ... Its researchers in Atlanta reversed the genetics system to generate the 1918 flu virus....
Usher Sued For $10 Million For Allegedly Exposing Another Woman To Herpes
Edit Inquisitr 22 Jul 2017High winds bring in Parvo virus, take toll on dogs’ health
Edit The Times of India 22 Jul 2017
Trichy ... Being an air-borne disease, the Parvo virus has already infected several dogs in the city ... He blamed the public for not identifying the virus and not bringing the affected dogs to veterinary centres for treatment ... This is a major symptom ... Doctors advise five to seven days treatment to save the dogs from the virus ... Once infected by the disease, the dog will develop immunity to fight the virus ... RELATED. From around the web ... YAHOO! ... Rai....
Govt to provide not-yet-approved medicines in outbreaks
Edit The Japan News 22 Jul 2017
When the French National Institute of Health and Medical Research administered the drug to 80 Ebola patients on a test basis in 2014 and 2015, the death rate among patients who had a relatively low amount of the virus in their blood halved, from 30 percent to 15 percent ... ■ Ebola virus disease....
Study to map infections launched
Edit The Hindu 22 Jul 2017
A nationwide burden study has been launched to map dengue, chikungunya, and Japanese encephalitis, according to Soumya Swaminathan, secretary of Department of Health Research and Director-General of Indian Council of Medical Research (ICMR) ... Noting that virology was an important area in public health and research, she said most new emerging diseases were viral infections ... As of now, 20 laboratories could test for Zika virus, she said....
U.S. researchers discover how CRISPR proteins find their target
Edit People Daily 22 Jul 2017
researchers have discovered how Cas1-Cas2, the proteins responsible for the ability of the CRISPR immune system in bacteria to adapt to new viral infections, identify the site in the genome where they insert viral deoxyribonucleic acid (DNA) so they can recognize it later and mount an attack ... CRISPR immune system allows bacteria to adapt and defend against the viruses that infect them....
- 1
- 2
- 3
- 4
- 5
- Next page »
